Article: Ovarian clear cell carcinoma with choriocarcinomatous differentiation: Report of a rare and aggressive tumor

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleOvarian clear cell carcinoma with choriocarcinomatous differentiation: Report of a rare and aggressive tumor
AuthorsHu, YJ
Ip, PPC1
Chan, KKL1
Tam, KF1
Ngan, HYS1
Keywordschoriocarcinoma
clear cell carcinoma
neoadjuvant chemotherapy
nongestatational choriocarcinoma
ovarian carcinoma
Issue Date2010
PublisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.intjgynpathology.com
CitationInternational Journal Of Gynecological Pathology, 2010, v. 29 n. 6, p. 539-545 [How to Cite?]
DOI: http://dx.doi.org/10.1097/PGP.0b013e3181e7cc66
AbstractOvarian epithelial tumors of nongerm cell origin with true choriocarcinomatous differentiation are rare. To date, there are only 5 documented cases in the literature. In the reported cases, the epithelial component was of mixed cell types or of mucinous differentiation. To the best of our knowledge, an ovarian carcinoma exclusively of clear cell differentiation coexisting with a pure choriocarcinoma has not been reported earlier. A 48-year-old postmenopausal woman was found to have a large pelvic mass with lung and liver metastases. Trucut biopsy of the mass showed a poorly differentiated carcinoma that was immunoreactive for CK7 and hCG. She received 6 cycles of neoadjuvant chemotherapy that included 3 cycles of etoposide/cisplatin and 3 cycles of paclitaxel/etoposide-paclitaxel/carboplatin (TE/TP) with partial response. Debulking surgery was carried out subsequently. Pathologic examination showed an ovarian clear cell carcinoma with a second component of choriocarcinoma in which the bilaminar growth pattern of cytotrophoblast and syncytiotrophoblasts was striking. Despite additional therapy, which included 2 cycles of TE/TP and 2 cycles of gemcitabine/taxotere, the disease progressed and the patient died 11 months postoperatively. This report showed that ovarian clear cell carcinoma with choriocarcinomatous differentiation is a highly aggressive tumor and has a very poor prognosis. Nonetheless, there may be a role for neoadjuvant chemotherapy that targets both the clear cell and the choriocarcinoma components to reduce the volume of the disease before debulking surgery. © 2010 International Society of Gynecological Pathologists.
ISSN0277-1691
2011 Impact Factor: 1.453
2011 SCImago Journal Rankings: 0.130
DOIhttp://dx.doi.org/10.1097/PGP.0b013e3181e7cc66
ISI Accession Number IDWOS:000283264400006
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorHu, YJ
dc.contributor.authorIp, PPC
dc.contributor.authorChan, KKL
dc.contributor.authorTam, KF
dc.contributor.authorNgan, HYS
dc.date.accessioned2011-07-27T01:39:12Z
dc.date.available2011-07-27T01:39:12Z
dc.date.issued2010
dc.description.abstractOvarian epithelial tumors of nongerm cell origin with true choriocarcinomatous differentiation are rare. To date, there are only 5 documented cases in the literature. In the reported cases, the epithelial component was of mixed cell types or of mucinous differentiation. To the best of our knowledge, an ovarian carcinoma exclusively of clear cell differentiation coexisting with a pure choriocarcinoma has not been reported earlier. A 48-year-old postmenopausal woman was found to have a large pelvic mass with lung and liver metastases. Trucut biopsy of the mass showed a poorly differentiated carcinoma that was immunoreactive for CK7 and hCG. She received 6 cycles of neoadjuvant chemotherapy that included 3 cycles of etoposide/cisplatin and 3 cycles of paclitaxel/etoposide-paclitaxel/carboplatin (TE/TP) with partial response. Debulking surgery was carried out subsequently. Pathologic examination showed an ovarian clear cell carcinoma with a second component of choriocarcinoma in which the bilaminar growth pattern of cytotrophoblast and syncytiotrophoblasts was striking. Despite additional therapy, which included 2 cycles of TE/TP and 2 cycles of gemcitabine/taxotere, the disease progressed and the patient died 11 months postoperatively. This report showed that ovarian clear cell carcinoma with choriocarcinomatous differentiation is a highly aggressive tumor and has a very poor prognosis. Nonetheless, there may be a role for neoadjuvant chemotherapy that targets both the clear cell and the choriocarcinoma components to reduce the volume of the disease before debulking surgery. © 2010 International Society of Gynecological Pathologists.
dc.description.natureLink_to_subscribed_fulltext
dc.identifier.citationInternational Journal Of Gynecological Pathology, 2010, v. 29 n. 6, p. 539-545 [How to Cite?]
DOI: http://dx.doi.org/10.1097/PGP.0b013e3181e7cc66
dc.identifier.doihttp://dx.doi.org/10.1097/PGP.0b013e3181e7cc66
dc.identifier.epage545
dc.identifier.hkuros186767
dc.identifier.hkuros188236
dc.identifier.isiWOS:000283264400006
dc.identifier.issn0277-1691
2011 Impact Factor: 1.453
2011 SCImago Journal Rankings: 0.130
dc.identifier.issue6
dc.identifier.pmid20881859
dc.identifier.scopuseid_2-s2.0-78149285342
dc.identifier.spage539
dc.identifier.urihttp://hdl.handle.net/10722/135675
dc.identifier.volume29
dc.languageeng
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.intjgynpathology.com
dc.publisher.placeUnited States
dc.relation.ispartofInternational Journal of Gynecological Pathology
dc.relation.referencesReferences in Scopus
dc.subject.meshAdenocarcinoma, Clear Cell - pathology - therapy
dc.subject.meshAntineoplastic Agents - therapeutic use
dc.subject.meshChoriocarcinoma, Non-gestational - pathology - therapy
dc.subject.meshGynecologic Surgical Procedures
dc.subject.meshOvarian Neoplasms - pathology - therapy
dc.subjectchoriocarcinoma
dc.subjectclear cell carcinoma
dc.subjectneoadjuvant chemotherapy
dc.subjectnongestatational choriocarcinoma
dc.subjectovarian carcinoma
dc.titleOvarian clear cell carcinoma with choriocarcinomatous differentiation: Report of a rare and aggressive tumor
dc.typeArticle
Author Affiliations
  1. The University of Hong Kong